Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) appointed Prafulla Gokhale, Ph.D., to its Scientific Advisory Board on Feb 26, 2026. Dr. Gokhale brings 20 years in preclinical oncology, RNA biology and translational therapeutics to support advancement of AKTX-101 and the company’s PH1 spliceosome-modulating payload toward first-in-human studies.
His experience directing translational programs and integrating genomics, patient-derived models and imaging is expected to refine AKTX-101's clinical strategy and translational experiments.
Akari Therapeutics (Nasdaq: AKTX) appointed Olga Anczukow, Ph.D., to its Scientific Advisory Board on February 23, 2026. Dr. Anczukow is an internationally recognized RNA biology and cancer researcher with roles at The Jackson Laboratory and University of Connecticut.
The appointment reinforces Akari's focus on advancing its PH1 ADC payload that targets RNA splicing in cancer cells and aims to strengthen translational research and scientific strategy.
Akari Therapeutics (Nasdaq: AKTX) announced that CEO Abizer Gaslightwala will present in person at the 2026 Biocom Global Partnering & Investor Conference.
The presentation is scheduled for Wednesday, February 25, 2026 at 11:00 AM PST in Track B, and management will be available for one-on-one meetings with registered investors.
Akari Therapeutics (Nasdaq: AKTX) CEO Abizer Gaslightwala joined a Virtual Investor “What This Means” interview on Feb. 11, 2026 to discuss the company’s expanded ADC pipeline, a recent patent filing, and the introduction of second ADC candidate AKTX-102 targeting CEACAM5 tumors.
The segment reviewed the scalability of Akari’s PH1-powered ADC platform, the company’s differentiated CEACAM5 antibody construct, execution priorities for lead program AKTX-101 as it advances toward IND and CTA submissions, and the strategic role of a growing patent estate to support partnering and long-term value creation.
Akari Therapeutics (Nasdaq: AKTX) will present a live video webcast on Tuesday, February 10, 2026 at 1:00 PM EST as part of Webull Financial’s Corporate Connect Webinar Series.
CEO Abizer Gaslightwala will provide a corporate overview of Akari’s ADC platform, the proprietary PH1 spliceosome‑modulating payload, lead program AKTX‑101 (Trop2‑targeting ADC), IND‑enabling activities toward a first‑in‑human trial in late 2026 or early 2027, and a brief update on AKTX‑102.
Akari Therapeutics (NASDAQ: AKTX) filed U.S. provisional patent No. 63/958,508 for AKTX-102, a CEACAM5-targeted ADC that pairs a novel antibody construct with Akari’s PH1 spliceosome payload.
The filing claims composition-of-matter protection for antibody design and ADC constructs and expands Akari’s PH1 patent family. CEACAM5 expression cited: 80–90% of gastrointestinal cancers, ~30% bladder, 25% lung adenocarcinomas, up to 50% luminal A breast. Akari plans IND-enabling work for AKTX-101 with FDA interactions in H1 2026 and aims for IND/CTA submission end-2026/early-2027.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner featuring CEO Abizer Gaslightwala summarizing 2025 progress and steps toward a clinical transition in 2026. The update highlights advancement of a novel ADC payload platform built on the proprietary PH1 spliceosome‑modulating payload, described as having a dual mechanism of direct tumor cytotoxicity plus immune activation and a compelling preclinical efficacy and safety profile. In 2025 the company announced a strategic manufacturing partnership with WuXi Biologics and began CMC and pre‑filing activities to support clinical readiness. Akari plans to initiate a First‑in‑Human trial as early as the end of 2026.
Akari Therapeutics (Nasdaq: AKTX) will present in person at the 2026 Biotech Showcase in San Francisco on Tuesday, January 13, 2026 at 9:30 AM PST in Yosemite A (Ballroom Level).
Abizer Gaslightwala, President and CEO, will overview Akari’s ADC platform, strategic priorities and key milestones for 2026. Management will also be available for in-person one-on-one meetings with registered, qualified investors during the conference running January 12–14, 2026.
Akari Therapeutics (Nasdaq: AKTX) issued its 2025 end-of-year letter outlining progress advancing antibody drug conjugates (ADCs) built on its proprietary PH1 payload, a spliceosome-modulating mechanism. Key 2025 milestones include: initiation of GMP manufacturing with WuXi XDC to support clinical supply, filing three new patents on the PH1 payload in H2 2025, preclinical activity of lead ADC AKTX-101 across pancreatic (KRAS), urothelial, gastric and AR-V7 prostate models, and differentiated safety in non-human primates. Akari plans regulatory interactions and aims to submit IND/CTA enabling a Phase 1 start in late 2026 or early 2027, subject to regulatory clearance.
Akari Therapeutics (Nasdaq: AKTX) has initiated GMP manufacturing for its lead ADC program, AKTX-101, selecting WuXi XDC as exclusive CDMO partner to perform IND-enabling work.
AKTX-101 uses Akari’s proprietary PH1 payload, described as an RNA-splicing modulator combining cytotoxic and immuno-oncology mechanisms. Akari expects this GMP material to support a Phase 1 first-in-human study planned for late 2026 or early 2027, subject to regulatory clearance.